Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cross-Reacting Material 197 (CRM197)
- Target
- CRM197
- Molecular classification
- Mutant Protein, Carrier Protein, Toxin Derivative
01
Overview
CRM197 is a genetically detoxified, non-toxic mutant of diphtheria toxin. It is widely used as a carrier protein in conjugate vaccines to enhance the immunogenicity of polysaccharides and haptens, which are otherwise poorly immunogenic on their own. By covalently linking these antigens to CRM197, the immune system can mount a stronger and more effective T-cell-dependent response. Beyond vaccines, CRM197 has been explored as a drug delivery vehicle and a component in cancer therapies.
- Other names
- Corynebacterium diphtheriae CRM197 protein
02
Mechanism of action
Conjugation to polysaccharide or hapten antigens to elicit T-cell dependent immune responses.
03
Biological functions
Carrier for vaccine antigensInduction of T-cell dependent immune responseFacilitating antigen presentation
04
Disease associations
Prevention of bacterial infections (e.g., Streptococcus pneumoniae, Haemophilus influenzae type b, Neisseria meningitidis)Drug delivery vehicleCancer therapy (targeting HB-EGF-overexpressing tumors)
05
Safety considerations
Potential cytotoxicity towards yeast or certain mammalian cell lines under specific circumstances
Beyond the preview
Go deeper on Cross-Reacting Material 197 (CRM197).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cross-Reacting Material 197 (CRM197).